Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.66 |
| ▸ | JAK3 | P52333 | 10/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.56 |
| ▸ | JAK1 | P23458 | 2/20 | 0.53 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16478873 | 0.93 | JAK2 (0.68) | JAK2JAK3HDAC1HDAC6PKMYT1 | |
| SCHEMBL2860948 | 0.93 | JAK2 (0.66) | JAK2JAK3HDAC1HDAC6PKMYT1 | |
| SCHEMBL13253185 | 0.88 | JAK2 (0.61) | JAK2JAK3HDAC1HDAC6PKMYT1 | |
| SCHEMBL2853691 | 0.87 | JAK2 (0.75) | JAK2JAK3HDAC1HDAC6PKMYT1 | |
| SCHEMBL13253910 | 0.83 | JAK2 (0.62) | JAK2JAK3HDAC1HDAC6PKMYT1 | |
| SCHEMBL30053325 | 0.82 | JAK2 (0.63) | JAK2JAK3HDAC1HDAC6PKMYT1 | |
| SCHEMBL2859057 | 0.82 | JAK2 (0.63) | JAK2JAK3HDAC1HDAC6PKMYT1 | |
| SCHEMBL22098006 | 0.81 | JAK1 (0.54) | JAK2JAK3JAK1TYK2STAT3 | |
| SCHEMBL4378045 | 0.80 | JAK2 (1.00) | JAK2JAK3HDAC1HDAC6JAK1 | |
| SCHEMBL4383566 | 0.77 | JAK2 (0.77) | JAK2JAK3HDAC1HDAC6JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | GLAXOSMITH KLINE LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | SIERRA ONCOLOGY, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2021-10-07 | — | — | US | disclosed |
| EP-3023422-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BioSciences Australia Pty Ltd (AU) | 2016-05-25 | — | — | EP | disclosed |
| US-9238628-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM Biosicences Australia PTY LTD (US) | 2016-01-19 | — | — | US | disclosed |
| US-9233934-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2152701-B1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2015-11-11 | — | — | EP | disclosed |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-02 | — | — | US | disclosed |
| US-8486941-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-07-16 | — | — | US | disclosed |
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | disclosed |
| EP-2152701-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | Cytopia Research Pty Ltd (AU) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008109943-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD (AU) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885HDAC1 4202/4885 |
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | JAK1, JAK2, JAK3 | JAK2 2/4885JAK3 3/4885HDAC1 1715/4885 |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885HDAC1 4202/4885 |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885HDAC1 4202/4885 |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885HDAC1 4202/4885 |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885HDAC1 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.